Education
About Us
Working with TipRanks
Follow Us
Sarepta Therapeutics Inc. (SRPT)
NASDAQ:SRPT
SRPT Stock Chart & Stats
$16.84
$1.44(1.16%)
At close: 4:00 PM EST
$16.84
$1.44(1.16%)
Day’s Range― - ―
52-Week Range$10.42 - $80.98
Previous CloseN/A
Volume185.86K
Average Volume (3M)2.35M
Market Cap
$1.77B
Enterprise Value$2.04B
Total Cash (Recent Filing)$939.65M
Total Debt (Recent Filing)$1.04B
Price to Earnings (P/E)―
Beta1.39
Next Earnings
May 06, 2026EPS Estimate
1.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.93
Shares Outstanding104,989,770
10 Day Avg. Volume2,484,756
30 Day Avg. Volume2,354,273
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.98
Price to Sales (P/S)1.03
P/FCF Ratio-7.33
Enterprise Value/Market Cap1.15
Enterprise Value/Revenue0.93
Enterprise Value/Gross Profit1.50
Enterprise Value/Ebitda-3.29
Forecast
1Y Price Target
$21.28Price Target Upside26.37% Upside
Rating ConsensusHold
Number of Analyst Covering21
EPS Forecast (FY)3.12
Revenue Forecast (FY)$1.74B
Bulls Say, Bears Say
Bulls Say
Clinical DataLonger-term EMBARK study data show larger improvements across multiple functional measures versus external controls with no new safety signals, strengthening the efficacy case for Elevidys and helping educate physicians on its benefit-risk profile.
Commercial StrategyManagement plans to restart the Elevidys commercial campaign with a much-expanded salesforce to increase physician outreach and patient uptake.
Real-world Evidence And KOL SupportComprehensive real-world evidence and favorable feedback from key opinion leaders indicate a positive risk/benefit profile for ambulatory patients and support continued payer coverage and adoption of exon-skipping therapies.
Bears Say
Competition And Market SentimentCompetition from other gene therapies and exon-skipping products, alongside analyst Sell or High Risk ratings and limited expected commercial upside, could constrain market share and investor confidence.
Financial And Operating PressureConservative revenue guidance and signals of materially higher operating expenses increase downside pressure on profitability and reduce near-term revenue expectations for the business.
Safety UncertaintyLiver toxicity risks inherent to adeno-associated viral gene therapies, coupled with an unclear link between dystrophin production and clinical benefit, create ongoing regulatory and clinical uncertainty for Elevidys.
Sarepta Therapeutics News
SRPT FAQ
What was Sarepta Therapeutics Inc.’s price range in the past 12 months?
Sarepta Therapeutics Inc. lowest stock price was $10.41 and its highest was $80.98 in the past 12 months.
What is Sarepta Therapeutics Inc.’s market cap?
Sarepta Therapeutics Inc.’s market cap is $1.77B.
When is Sarepta Therapeutics Inc.’s upcoming earnings report date?
Sarepta Therapeutics Inc.’s upcoming earnings report date is May 06, 2026 which is in 48 days.
How were Sarepta Therapeutics Inc.’s earnings last quarter?
Sarepta Therapeutics Inc. released its earnings results on Feb 25, 2026. The company reported -$3.93 earnings per share for the quarter, missing the consensus estimate of -$1.197 by -$2.733.
Is Sarepta Therapeutics Inc. overvalued?
According to Wall Street analysts Sarepta Therapeutics Inc.’s price is currently Undervalued.
Does Sarepta Therapeutics Inc. pay dividends?
Sarepta Therapeutics Inc. does not currently pay dividends.
What is Sarepta Therapeutics Inc.’s EPS estimate?
Sarepta Therapeutics Inc.’s EPS estimate is 1.05.
How many shares outstanding does Sarepta Therapeutics Inc. have?
Sarepta Therapeutics Inc. has 104,989,770 shares outstanding.
What happened to Sarepta Therapeutics Inc.’s price movement after its last earnings report?
Sarepta Therapeutics Inc. reported an EPS of -$3.93 in its last earnings report, missing expectations of -$1.197. Following the earnings report the stock price went down -8.013%.
Which hedge fund is a major shareholder of Sarepta Therapeutics Inc.?
Currently, no hedge funds are holding shares in SRPT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sarepta Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$21.28 (26.37% Upside)
$21.28 (26.37% Upside)
Blogger Sentiment
Bullish
SRPT Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 33.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $417.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
News Sentiment
Very Bearish
Bullish news 19%
Bearish news 83%
Bearish news 83%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-76.66%
12-Months-Change
Fundamentals
Return on Equity
-57.52%
Trailing 12-Months
Asset Growth
-15.48%
Trailing 12-Months
Company Description
Sarepta Therapeutics Inc.
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
SRPT Company Deck
SRPT Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call balanced material near-term challenges (safety-related market uncertainty, substantial inventory/manufacturing charges and reported operating losses) with strong underlying positives: robust revenue growth in 2025, a solid cash position, compelling and durable three‑year ELEVIDYS efficacy data, a stable PMO franchise, a rapidly advancing siRNA pipeline with multiple clinical programs and clear 2026 financial guidance. Management emphasized plans to address information deficits, commercial expansion and pipeline milestones; timing risk for ELEVIDYS uptake and non-ambulatory resumption remains notable.View all SRPT earnings summariesSRPT Stock 12 Month Forecast
Average Price Target
$21.28
▲(26.37% Upside)
Technical Analysis
BioCryst
―
Mesoblast
―
Cogent Biosciences
―
Arcutis Biotherapeutics
―
Dyne Therapeutics
―
Ownership Overview
5.16% Insiders
15.79% Mutual Funds
12.42% Other Institutional Investors
37.50% Public Companies and Individual Investors